Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

4099 - A first-in-human (FIH) phase I/II, dose escalation, pharmacokinetic (PK) study to assess the safety and tolerability of VAL-201 in patients with advanced prostate cancer (APC) and other advanced solid tumours


10 Oct 2016


Poster display


Rebecca Kristeleit


Annals of Oncology (2016) 27 (6): 114-135. 10.1093/annonc/mdw368


R.S. Kristeleit1, R.E. Miller2, L.E. Sellers3, N.F. Brown2, P. Gougis2, A. Boyd4, G. Morris5, H. Payne3, S. Hughes6, M. Forster1, M. Linch3

Author affiliations

  • 1 Cancer Institute, UCL - University College London, WC1E 6DD - London/GB
  • 2 Uclh/nihr Clinical Research Facility, University College London Hospital, W1T 7HA - London/GB
  • 3 Oncology, University College London Hospital, N1 2BU - London/GB
  • 4 Boyd, Consulting, London/GB
  • 5 Coo, ValiRx, London/GB
  • 6 Oncology, Guy's and St. Thomas' Hospital NHS Trust, London/GB


Abstract 4099


Most patients with advanced prostate cancer treated with androgen deprivation therapy experience side effects of castration and eventually relapse. VAL-201 is a synthetic decapeptide that inhibits interaction of the androgen and oestradiol receptors with Src tyrosine kinase, disrupting steroid or epithelial growth factor dependent DNA synthesis. The aims of this FIH study are to assess safety, tolerability, PK and activity of VAL-201 in patients with APC.


An accelerated titration, open label, dose-escalating design has been used to identify a maximum tolerated/administered dose (MTD/MAD). VAL-201 is given subcutaneously on Days 1, 8, 15, q21. The starting dose was 0.5 mg/kg. Expansion to a 3 + 3 design was planned to occur at dose level (DL) 3. Dose limiting toxicity (DLT) was assessed during Cycle 1 and safety evaluations were conducted weekly.


Eight patients have been recruited to 4 DLs (0.5mg/kg n = 1; 1.0mg/kg n = 1; 2.0mg/kg n = 3; 4.0mg/kg n = 3). Patient demographics are in Table 1. The final planned escalation will be 5.0mg/kg, the maximum feasible single dose which may be administered. No DLT has occurred to date. The only drug-related adverse event (AE) observed has been Grade 1 injection site reaction. Median duration on trial is currently 85 days. Early signs of clinical activity have been observed with prolonged PSA doubling time (n = 2), stabilisation of PSA (n = 1) and >50% decrease in PSA (n = 1, Table).

Patient # Dose cohort Age ECOG PS days on trial Disease status Castrate sensitivity PSA doubling pre-trial (months)** PSA doubling on trial (months)
>101-001 0.5mg/kg 71 0 191 locally advanced resistant 2.8 7.5
101-003 1.0mg/kg 63 0 126 locally advanced sensitive 13.3 6.1
101-005 2.0mg/kg 79 1 85 metastatic resistant 1.6 2.2
101-006 2.0mg/kg 70 0 55 metastatic sensitive 1.9 1.6
101-007 2.0mg/kg 81 0 64 locally advanced sensitive 12.5 8.2
101-008 4.0mg/kg 68 1 55* metastatic resistant 2.9 -2.2
101-009 4.0mg/kg 82 0 40* locally advanced sensitive 2.9 -97.5
101-010 4.0mg/kg 84 0 -7* locally advanced sensitive 6 NA

*continues on study **minimum of three months


VAL-201 is very well-tolerated with early signs of clinical activity in advanced prostate cancer. No DLT has been observed. The MTD/MAD has not yet been identified and the study continues. Expansion to other tumour types is planned. PK data analysis is ongoing and will be presented.

Clinical trial identification


Legal entity responsible for the study



ValiRx, Inc


A. Boyd: Is employed as a Consultant by ValiRx as a medical monitor for the trial. G. Morris: Employee of ValiRx.All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings